(Q37972757)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212568%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212568%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212568%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1

Michael P Manns

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212568%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Antoaneta A Markova

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212568%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

Beatriz Calle Serrano

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212568%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212568%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212568%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

32 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212568%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

27-31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22212568%20AND%20SRC:MED&resulttype=core&format=json

The way forward in HCV treatment--finding the right path

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X

Hepatitis in 2010: the dawn of a new era in HCV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bio

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X

Hepatitis C and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2011.02725.X